Abstract:
Reactive arthritis (Re!) is an inflammatory joint disease triggered by urogenital or enteric infections. This 52-week prospective cohort from Uzbekistan compared the TNF-α inhibitor golimumab and the J!K inhibitor tofacitinib in 60 Re! patients. Both treatments produced significant reductions in D!RE!, B!SD!I, and inflammatory markers. Mean D!RE! decreased from 4.7 to 1.6 with golimumab and from 4.5 to 1.1 with tofacitinib (p < 0.001). Cytokine levels (TNF-α, IL-17!) declined by over 40%, correlating with clinical improvement. !dverse events were mild, and no thromboembolic or fatal outcomes occurred. Tofacitinib achieved slightly faster and deeper responses, supporting its role as an effective oral alternative to biologic therapy in resource-limited settings.
